Search Results Table
| Result Summary | |||
|---|---|---|---|
| S.3141 |
8
|
Kilcoyne, Meghan K. |
Patient Access to Biomarker Testing to Provide Appropriate Therapy
(a) As used in this section ... or -cleared test; 2. Indicated tests for an FDA-approved drug; 3. Warnings and precautions on FDA-approved drug labels; 4. Centers for Medicare ... |
| S.3141 |
59
|
Arciero, James |
Co-Pay Accumulator Exclusion of Generic Equivalents
a prescription drug for which an FDA-approved, therapeutically equivalent generic drug is ... |
| H.4530 |
7
|
Soter, Michael J. |
Coverage for GLP-1's for GIC Employees
obesity; or (iii) any other indication for which such medication has received FDA approval ... of “medical necessity” narrower than the FDA-approved indications, nor shall coverage be ... |
| S.3141 |
87
|
Ashe, Brian M. |
Addressing a copay assistance gap
by inserting into section 29 the following ... “FDA”, the federal Food and Drug Administration ... its coverage of a branded drug because the FDA has approved an equivalent drug until such ... |
| H.4601 |
30
|
Finn, Michael J. |
Substance Use Disorder Treatment Coverage
payment of medical assistance for FDA approved long-acting injectable or extended-release ... This payment shall be unbundled from the hospital daily rate |
| H.5500 |
1693
|
Decker, Marjorie C. |
Maintaining Patient Access to Care
all members who do not have an FDA-approved comorbidity”; and moves to further amend the ... |
| H.4187 |
7
|
Vaughn, Marcus S. |
THC Warning Labels
by adding the following section: SECTION XXXX ... including capitalization: ''This product has not been analyzed or approved by the FDA ... There is limited information on the side effects ... |